Jan Marini Skin Research is withdrawing from the U.S. market an eyelash cosmetic after the FDA alleged an ingredient in the product is similar to a prescription drug. Meanwhile, Allergan, maker of glaucoma drug Lumigan, announced last week it was dropping one of seven defendants in its patent-infringement lawsuit against eyelash-product companies.

Related Summaries